GlobeNewswire

NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
10/11/2026
Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, [...]
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
10/11/2026
Completed enrollment in the Phase II COVALENT-211 clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes (“T2D”); topline data expected in the first quarter of 2027 Enrollment ongoing in [...]
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
10/11/2026
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
10/11/2026
FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for [...]
Bionano Reports Third Quarter 2026 Results and Provides a Business Update
10/11/2026
Conference call today, November 10, 2026, at 4:30 PM ET SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2026 [...]
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
10/11/2026
Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 Major BLA amendment added two-year open-label extension (OLE) HOPE-3 [...]
PetMeds® Announces Second Quarter Financial Results
10/11/2026
DELRAY BEACH, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026 [...]
Lumexa Imaging Announces Third Quarter 2026 Results
10/11/2026
RALEIGH, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the third quarter ended September 30, 2026 [...]
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
10/11/2026
BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized. BACKBEAT Trial primary endpoint data planned to be submitted for late- [...]
Spectral AI Announces 2026 Third Quarter Financial Results
10/11/2026
Remains on Track for First U.S. Commercial Placement of the DeepView AI System in the Fourth Quarter of 2026 DALLAS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), [...]
BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
10/11/2026
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC patients BBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant [...]
Precipio Announces Q3-2026 Financial Results
10/11/2026
Record quarterly revenue, positive Adjusted EBITDA, and strong operating cash flow - all position Precipio for accelerated future growth NEW HAVEN, Conn., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics [...]
Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program
10/11/2026
VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
10/11/2026
CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT [...]
Anaptys Announces Participation in Upcoming Investor Conferences
10/11/2026
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, [...]
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
10/11/2026
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027 New Clinical and [...]
Aro Biotherapeutics Reports Therapeutic Potential of Centyrin–CD40 siRNA Conjugate for the Treatment of Inflammatory Myositis
10/11/2026
Oral presentation at ACR Convergence uncovers the role of the CD40 pathway in myositis and potential therapeutic benefit of ABX1200, a novel CD71-Centyrin CD40-siRNA conjugate PHILADELPHIA, Nov. 10, 2026 (GLOBE NEWSWIRE [...]
The Cooperative of American Physicians, Inc. Promotes Andrew Cate, JD, to Senior Vice President of CAP Claims Services
10/11/2026
LOS ANGELES, Nov. 10, 2026 (GLOBE NEWSWIRE) -- The Cooperative of American Physicians, Inc. (CAP) announced the promotion of Andrew Cate, JD, to Senior Vice President of CAP Claims Services. CAP provides medical [...]
Sanuwave Announces Q3 FY2026 Financial Results
10/11/2026
Q3 2026 revenues were $8.6 million , down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3% , versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum